Skip to main content
SpringerLink
Log in

Chronic Obstructive Pulmonary Disease

Mortality and Mortality Reduction

  • Section 4: Keynote Presentations
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Chronic obstructive pulmonary disease (COPD) affects an estimated 15 million Americans and is the fourth most common cause of death in the US. Despite an improved understanding of the disease, treatment has changed little over the past 20 to 30 years and COPD remains a major health problem worldwide.

Smoking is the major risk factor for COPD, accounting for some 90% of cases. Therefore, smoking cessation remains the most important intervention. Other available pharmacotherapeutic options include corticosteroids, bronchodilators, antibiotics for the treatment of acute exacerbations, mucokinetic agents, and oxygen for the advanced stages of the disease. Recent data investigating the use of dornase alfa (recombinant human deoxyribonuclease I) in patients with acute exacerbations of COPD were disappointing and failed to demonstrate a mortality benefit.

While it is likely that ongoing research will optimise the use of older agents and identify new treatment options for patients with COPD, smoking cessation will probably remain the most important intervention and should be a key focus of future initiatives aimed at controlling this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Higgins MW, Thorn T. Incidence, prevalence, and mortality: intra- and inter-country differences. In: Hensley MJ, Saunders NA, editors. Clinical epidemiology of chronic obstructive pulmonary disease. New York: Marcel Dekker, 1990; 23–43

    Google Scholar 

  2. Anon. Trends in smoking initiation among young adolescents and young adults — United States, 1980–1989. MMWR 1995; 44: 522–5.

  3. American Thoracic Society. Medical Section of the American Lung Association. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. In press

  4. Orie NG, Sluiter HJ, DeVries K, et al. The host factor in bronchitis. In: Orie NG, Sluiter HJ, editors. Bronchitis. Assen: Royal Vangorcum, 1961; 43–59

    Google Scholar 

  5. US Surgeon General. The health consequences of smoking: chronic obstructive lung disease. DHHS publ. no. 84-50205. Washington: US Department of Health and Human Services, 1984.

    Google Scholar 

  6. Xu X, Dockery DW, Ware JH, et al. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. Am Rev Respir Dis 1992; 146: 1345–8.

    PubMed  CAS  Google Scholar 

  7. Burrows B. Course and prognosis in advanced disease. In: Petty TL, editor. Chronic obstructive pulmonary disease. New York: Marcel Dekker, 1985: 31–42.

    Google Scholar 

  8. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 6077: 1645–8.

    Article  Google Scholar 

  9. Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993; 118: 770–8.

    PubMed  CAS  Google Scholar 

  10. Van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303: 1426–31.

    Article  PubMed  Google Scholar 

  11. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497–1505.

    Article  PubMed  CAS  Google Scholar 

  12. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957–60.

    Article  PubMed  CAS  Google Scholar 

  13. Siafakas NM, Vermeire P, Pride NB, et al. ERS — consensus statement: optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398–1420.

    Article  PubMed  CAS  Google Scholar 

  14. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26.

    Google Scholar 

  15. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Nat Acad Sci USA 1990; 87: 9188–9211.

    Article  PubMed  CAS  Google Scholar 

  16. Bryson HM, Sorkin EM. Dornase alfa: a review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994; 48: 894–906.

    Article  PubMed  CAS  Google Scholar 

  17. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637–42.

    Article  PubMed  CAS  Google Scholar 

  18. Bone RC, Fuchs H, Fox NL, et al. The chronic obstructive pulmonary disease mortality endpoint trial [abstract]. Chest 1995; 108 Suppl.: R.

    Google Scholar 

  19. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–6.

    Google Scholar 

  20. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary and Critical Care Medicine, Medical College of Pennsylvania and Hahnemann University School of Medicine, 3300 Henry Avenue, Philadelphia, Pennsylvania, 19129, USA

    Stanley B. Fiel

Authors
  1. Stanley B. Fiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiel, S.B. Chronic Obstructive Pulmonary Disease. Drugs 52 (Suppl 2), 55–61 (1996). https://doi.org/10.2165/00003495-199600522-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199600522-00012

Keywords

Search

Navigation